We have filed patent application to protect our intellectual advancement in the tool for Biologic discovery. The well crafted VADEX-pro technology has shown its potential as the essential technology for generating and screening of Ultra-High affinity (KD<1E-12 M) monoclonal antibodies for diagnostic and therapeutic applications. Been a self-adjuvanted protein nanoparticle, VADEX-pro is able to continuously stimulates immune system long after immunization and breaks the binding affinity ceiling that prevents scientists from obtaining ultra-high affinity monoclonal antibodies. Since the binding affinity is closely related to the the specificity of diagnostic and the efficacy of therapeutic monoclonal antibodies, we believe VADEX-pro will serve as an essential tool for the further improvement of human health!